Juho Jalkanen

Juho Jalkanen

Company: Faron Pharmaceuticals

Job title: Chief Operating Officer


Clinical Update on Bexmarilimab – the First-in-Class Anti-CLEVER-1 mAb 9:30 am

• FiH Phase I/II study showing extended survival in last line patients • Review biomarkers to identify responding patients • Outline future development plans based on the FiH Phase I/II resultsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.